Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell analysis, today’s sector results tells its own story – 36 of 43 covered down

November 2, 2016 5:08pm

… What’s behind the trading, pricing and volume that facilitated the downside?

The iShares Russell 2000 (IWM) was DOWN -1.26% at the close while the iShares Nasdaq Biotechnology (IBB) closed DOWN -1.84%.

… Headwinds are stronger as new lows heighten the sensitivity of material risks

The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, traded about 4.5% higher, near 19.4. The so-called fear gauge has also risen more than 16% this week.

I answer one question; in which company should investors put, keep and commit their money!

Lose an advantage or be a subscriber! Today’s results have implications to Thursday's sector activity.

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.